An au­toim­mune up­start turns PD-L1 around to blaze a new ap­proach to di­a­betes, mul­ti­ple scle­ro­sis

PD-L1 has be­come one of the most fa­mil­iar tar­gets in the glob­al can­cer re­search world, a key play­er in me­di­at­ing a co­or­di­nat­ed im­mune sys­tem as­sault on can­cer cells. 

But what if you could al­so turn it around, use el­e­vat­ed PD-L1 to muf­fle an au­toim­mune re­sponse by T cells, hit­ting the brakes on the im­mune sys­tem and avoid­ing an as­sault on healthy tis­sue — rather than tak­ing your foot off the brake and tar­get­ing can­cer­ous cells?

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.